FDA Approves BAQSIMI, The First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia


The U.S. Food and Drug Administration (FDA) has approved Lilly’s BAQSIMI (glucagon) nasal powder 3 mg for the treatment of severe hypoglycemia in people with diabetes ages four years and above. BAQSIMI is the first and only nasally administered glucagon, and it was designed with severe hypoglycemia rescue in mind.

Severe hypoglycemia is a serious medical condition that constitutes an emergency for people with type 1 and type 2 diabetes. It is characterized by altered mental and/or physical functioning that requires assistance from another person for recovery. If untreated, severe hypoglycemia can lead to serious consequences, such as loss of consciousness, seizure, coma and death.

BAQSIMI is a portable, dry nasal spray form of glucagon, ready to use with no reconstitution or priming required in a single, fixed 3 mg dose. It is absorbed in the nose, so does not require inhalation. BAQSIMI does not need to be refrigerated and can be stored at temperatures up to 86°F/30°C in the shrink-wrapped tube provided.

Acquired by Lilly from Locemia Solutions in 2015, BAQSIMI is a new formulation of rescue glucagon. Dr. Claude Piche, CEO and co-founder of Locemia Solutions, credits co-founder Robert Oringer as the original inspiration behind BAQSIMI. Oringer has two sons diagnosed with type 1 diabetes. 

Leave a Reply

2 Comment threads
1 Thread replies
Most reacted comment
Hottest comment thread
3 Comment authors
Madeleine MulanixJ. KimbroughIvan Recent comment authors
newest oldest most voted
Notify of
J. Kimbrough
J. Kimbrough

Is Medicare going to pay for this? Does anyone know?


How much does it cost? How long can it be kept on the shelf unused?

Madeleine Mulanix
Madeleine Mulanix

Probably so expensive that the normal person won’t be able to afford it, just like many diabetes meds.

Copyright © 2009-2018 Diabetes Media Foundation, All Rights Reserved.
ASweetLife™ is a trademark of the Diabetes Media Foundation, All Rights Reserved.